Identifying cancer treatment targets using genetic analysis in mice
Defining Cancer Intervention Targets by Functional Genomics Analysis of Outbred F1 Mice
['FUNDING_R01'] · HENRY FORD HEALTH + MICHIGAN STATE UNIVERSITY HEALTH SCIENCES · NIH-11011468
This study is looking at how certain genes can help slow down breast cancer growth and stop it from coming back, using mice to find out more about a molecule called LILRB4 that affects how the immune system fights tumors, with the hope of discovering new ways to improve treatment for patients.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | HENRY FORD HEALTH + MICHIGAN STATE UNIVERSITY HEALTH SCIENCES (nih funded) |
| Locations | 1 site (EAST LANSING, UNITED STATES) |
| Trial ID | NIH-11011468 on ClinicalTrials.gov |
What this research studies
This research investigates how targeting specific regulatory genes can slow down tumor growth and prevent cancer from returning. By studying genetically diverse mice that develop breast tumors, researchers aim to identify key genes involved in cancer progression and test new treatment strategies. The study focuses on a molecule called LILRB4, which plays a role in how the immune system interacts with tumors. Through advanced genetic analysis and bioinformatics, the research seeks to uncover actionable targets that could improve cancer treatment outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with breast or lung cancer, particularly those with HER2/neu expression.
Not a fit: Patients with cancers unrelated to HER2/neu or those who do not express the targeted regulatory genes may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies that enhance anti-tumor immunity and improve survival rates for cancer patients.
How similar studies have performed: Previous research has shown promise in targeting similar regulatory genes for cancer treatment, indicating a potential for success in this approach.
Where this research is happening
EAST LANSING, UNITED STATES
- HENRY FORD HEALTH + MICHIGAN STATE UNIVERSITY HEALTH SCIENCES — EAST LANSING, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: JACOB, JENNIFER B — HENRY FORD HEALTH + MICHIGAN STATE UNIVERSITY HEALTH SCIENCES
- Study coordinator: JACOB, JENNIFER B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.